91619-41-9

Upstream product

• 121-51-7 3-nitrobenzenesulphonyl chloride 
• 91619-35-1 1-(3-nitrobenzenesulfonyl)-1,2,3,4-tetrahydroquinoline 
• 635-46-1 1,2,3,4-tetrahydroisoquinoline 

Downstream Products

• 263845-08-5 [3-(3,4-dihydro-2H-quinoline-1-sulfonyl)-phenyl]-bis-(3H-imidazol-4-ylmethyl)-amine 
• 905438-35-9 3-amino-N-[3-(3,4-dihydroquinolin-1(2H)-ylsulfonyl)phenyl]thiophene-2-carboxamide 
• 905438-36-0 Methyl 2-[({[3-(3,4-dihydroquinolin-1(2H)-ylsulfonyl)phenyl]amino}carbonyl)amino]thiophene-3-carboxylate 
• 905438-37-1 dimethyl 4-[({[3-(3,4-dihydroquinolin-1(2H)-ylsulfonyl)phenyl]amino}carbonyl)amino]thiophene-2,3-dicarboxylate 
• 847173-98-2 Methyl 2-[({[3-(3,4-dihydroquinolin-1(2H)-ylsulfonyl)phenyl]amino}carbonyl)amino]-6-nitrobenzoate 

Relevant academic research and scientific papers

NITROGENATED FUSED RING DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE OF THE SAME FOR MEDICAL PURPOSES

[Purpose] The present invention provides compounds useful as agents for the prevention or treatment of a sex hormone-dependent disease or the like. [Solution] The present invention provides nitrogen-containing fused ring derivatives represented by the following general formula (I) which has a GnRH antagonistic activity, prodrugs, salts, pharmaceutical compositions containing the same, medicinal uses thereof and the like. In the formula (I), rings A and B are independently aryl or heteroaryl; RA and RB are independently halogen, cyano, alkyl, alkylsulfonyl, -OW1, -SW1, -COW2, -NW3W4, -SO2NW3W4, aryl, etc.; RC is H or alkyl; E is oxygen atom, etc.; U is single bond or alkylene; and X is Y, -CO-Y, -SO2-Y -S-(alkylene)-Y, -O-(alkylene)-Y, -SO2-(alkylene)-Y, etc.; Y is Z or amino, etc.; and Z is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, etc.

FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME,AND MEDICINAL USE THEREOF

The present invention provides a compound useful as an agent for the prevention or treatment of a sex hormone-dependent disease or the like. That is, the present invention provides a fused heterocyclic derivative represented by the following general formula (I), a pharmaceutical composition containing the same, a medicinal use thereof and the like. In the formula (I), ring A represents 5-membered cyclic unsaturated hydrocarbon or 5-membered heteroaryl; RA represents halogen, alkyl, alkenyl, alkynyl, carboxy, alkoxy, carbamoyl, alkylcarbamoyl or the like; ring B represents aryl or heteroaryl; RB represents halogen, alkyl, carboxy, alkoxy, carbamoyl, alkylcarbamoyl or the like; E1 and E2 represent an oxygen atom or the like; U represents a single bond or alkylene; X represents a group represented by Y, -SO2-Y, -O-(alkylene)-Y, -O-Z in which Y represents Z, amino or the like; Z represents cycloalkyl, heterocycloalkyl, aryl, heteroaryl or the like; or the like.

FUSED PYRIMIDINE DERIVATIVE AND USES THEREOF

A compound represented by the formula (I) wherein ring A is a 5-membered aromatic heterocycle optionally having substituent(s), R1 is a hydrogen atom or a hydrocarbon group optionally having substituent(s), W is an oxygen atom or a sulfur atom, X1 and X2 may be the same or different and each is a hydrogen atom, a hydrocarbon group optionally having substituent(s) or a heterocyclic group, or, X1 and X2 in combination optionally form an oxygen atom, a sulfur atom or =NR2, ring B is an aromatic ring optionally further having substituent(s), Y is a bond, C1-6 alkylene C2-6 alkenylene or C2-6 alkynylene, optionally having substituent(s), and Z is a group represented by formula: -SOnR3, or a group represented by formula: -COR4, or a salt thereof, is useful as a pharmaceutical agent having GnRH antagonistic action.

FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF

There are provided a fused pyrimidine compound having antagonistic activity against luteinizing hormone releasing hormone, and a medicine containing the compound. A luteinizing hormone releasing hormone antagonist containing a compound represented by the formula: wherein R1a is a hydrocarbon group which may be substituted or a hydrogen atom, ring Aa is a 6-membered aromatic ring which may be further substituted, ring Ba is a homocyclic or heterocyclic ring which may be further substituted, Wa is an oxygen atom or a sulfur atom, Xa1 and Xa2, which may be identical or different, are each a hydrogen atom, a hydrocarbon group which may be substituted, or a heterocyclic group which may be substituted, or Xa1 and Xa2 together may form an oxygen atom, a sulfur atom or NR3a (wherein R3a is a hydrocarbon group which may be substituted or a hydrogen atom), and Ya is C1-6 alkylene which may be substituted or a bond, or a salt or prodrug thereof.

3-Imidazolymethylaminophenylsulfonytetrahydroquinolines, a novel series of farnesyltransferase inhibitors

Design, synthesis and structure-activity relationship of a series of 3-imidazolylmethylaminophenylsulfonyltetrahydroquinolines as farnesyltransferase inhibitors are presented. A working pharmacophore of inhibiting farnesyltransferase by this series of inhibitors is proposed. (C) 2000 Elsevier Science Ltd. All rights reserved.